ReviewAngewandte Chemie (International ed. in English)2021
Biopolymer-based Carriers for DNA Vaccine Design.
Review in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- DNA-based vaccines: Advances, applications, and future prospects.Genes & diseases · 2026Review
- The research progress of gastric cancer vaccines: a narrative review.Translational cancer research · 2026Review
- Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention.MedComm · 2026Review
- Targeted immunomodulation for chronic diseases through advanced delivery platforms.Expert opinion on drug delivery · 2026Review
- Article
- Effect of PEI25k/DOTAP/cholesterol liposomal formulation on the immunogenicity of SARS-CoV-2 spike protein-encoding DNA vaccine.Biotechnologia · 2026Article
- Polymeric particle-based antigen delivery system: From immunological engineering to clinical translation.International journal of pharmaceutics: X · 2025Review
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination.Medicines (Basel, Switzerland) · 2025Review
- An Update on Vaccines AgainstPathogens (Basel, Switzerland) · 2025Review
- Computer-aided designing of a novel multi‑epitope DNA vaccine against severe fever with thrombocytopenia syndrome virus.BMC infectious diseases · 2024Article
- Biomimetic Scaffolds-A Novel Approach to Three Dimensional Cell Culture Techniques for Potential Implementation in Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2024Review
- Multi-epitope vaccine design against leishmaniasis using IFN-γ inducing epitopes from immunodominant gp46 and gp63 proteins.Journal, genetic engineering & biotechnology · 2024Article
- Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.Signal transduction and targeted therapy · 2024Review
- Autophagy-modulating biomaterials: multifunctional weapons to promote tissue regeneration.Cell communication and signaling : CCS · 2024Review
- DNA Vaccines: Their Formulations, Engineering and Delivery.Vaccines · 2024Review
- Advanced biopolymeric materials and nanosystems for RNA/DNA vaccines: a review.Nanomedicine (London, England) · 2024Review
- Adjuvant DNA vaccine pNMM promotes enhanced specific immunity and anti-tumor effects.Human vaccines & immunotherapeutics · 2023Article
- Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants.Pharmaceutics · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last 30 years, genetically engineered DNA has been tested as novel vaccination strategy against various diseases, including human immunodeficiency virus (HIV), hepatitis B, several parasites, and cancers. However, the clinical breakthrough of the technique is confined by the low transfection efficacy and immunogenicity of the employed vaccines. Therefore, carrier materials were designed to prevent the rapid degradation and systemic clearance of DNA in the body. In this context, biopolymers are a particularly promising DNA vaccine carrier platform due to their beneficial biochemical and physical characteristics, including biocompatibility, stability, and low toxicity. This article reviews the applications, fabrication, and modification of biopolymers as carrier medium for genetic vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.